12:00 AM
Jan 16, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Jevtana cabazitaxel regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending against Jevtana cabazitaxel from Sanofi as a second-line treatment for prostate cancer in combination with prednisone or prednisolone. The recommendation is in line with a preliminary appraisal issued in September, despite an updated economic model provided...

Read the full 207 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >